Literature DB >> 1646664

Response to immunization against polio after allogeneic marrow transplantation.

P Ljungman1, V Duraj, L Magnius.   

Abstract

Long-term immunity to poliovirus and immunization response to inactivated poliovirus vaccine (IPV) were studied in 55 patients who underwent allogeneic bone marrow transplantation (BMT). Antibodies were determined by neutralization assays. Patients were studied before, at 12 months after BMT and at 12 months after immunization with IPV. Thirty-seven patients were seropositive to all poliovirus types at 12 months after BMT. At least a four-fold decrease in antibody level was recorded between BMT and 12 months later in 55%, 41%, and in 45% of the patients to poliovirus types 1, 2, and 3, respectively. Nineteen patients were immunized with one dose of trivalent IPV. Eight patients (42%), seven patients (36%), and four patients (21%) responded with at least a four-fold antibody titer increase to poliovirus type 1, 2, and 3, respectively. Twenty-nine patients were primarily immunized with three IPV doses. The response rates were 52%, 48% and 48% to poliovirus types 1, 2, and 3, respectively. The immunization responses were similar in patients who did or did not have chronic GVHD. Reimmunization of allogeneic BMT recipients against poliovirus is necessary and a three dose schedule is needed to obtain an adequate immunization response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646664

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies.

Authors:  Gunjan L Shah; Leyla Shune; Duncan Purtill; Sean Devlin; Emily Lauer; Marissa Lubin; Valkal Bhatt; Courtney McElrath; Nancy A Kernan; Andromachi Scaradavou; Sergio Giralt; Miguel A Perales; Doris M Ponce; James W Young; Monica Shah; Genovefa Papanicolaou; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-10       Impact factor: 5.742

2.  Immunization for bone marrow transplant recipients.

Authors:  B Lynn Johnston; John M Conly
Journal:  Can J Infect Dis       Date:  2002-11

3.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: persistent immune deficiency in pediatric transplant survivors.

Authors:  Nancy Bunin; Trudy Small; Paul Szabolcs; K Scott Baker; Michael A Pulsipher; Troy Torgerson
Journal:  Biol Blood Marrow Transplant       Date:  2011-11-17       Impact factor: 5.742

Review 4.  Immune reconstitution following bone marrow transplantation.

Authors:  U N Verma; A Mazumder
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

Review 5.  B cells and transplantation: an educational resource.

Authors:  Trudy N Small; William H Robinson; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

6.  Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction.

Authors:  V Hammarström; K Pauksen; J Azinge; G Oberg; P Ljungman
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

7.  Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.

Authors:  Timothy J Henrich; Zixin Hu; Jonathan Z Li; Gaia Sciaranghella; Michael P Busch; Sheila M Keating; Sebastien Gallien; Nina H Lin; Francoise F Giguel; Laura Lavoie; Vincent T Ho; Philippe Armand; Robert J Soiffer; Manish Sagar; Ann S Lacasce; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2013-03-04       Impact factor: 5.226

8.  Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.

Authors:  Andrew J Ullmann; Martin Schmidt-Hieber; Hartmut Bertz; Werner J Heinz; Michael Kiehl; William Krüger; Sabine Mousset; Stefan Neuburger; Silke Neumann; Olaf Penack; Gerda Silling; Jörg Janne Vehreschild; Hermann Einsele; Georg Maschmeyer
Journal:  Ann Hematol       Date:  2016-06-24       Impact factor: 3.673

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.